A study extending experience with raloxifene to 8 years shows no adverse impact on gynecologic health with longer-term use. Results of the Continuing Outcomes Relevant to EVISTA (CORE) trial build on and support previous findings from the 4-year Multiple Outcomes of Raloxifene Evaluation (MORE) trial.
A study extending experience with raloxifene to 8 years shows no adverse impact on gynecologic health with longer-term use. Results of the Continuing Outcomes Relevant to EVISTA (CORE) trial build on and support previous findings from the 4-year Multiple Outcomes of Raloxifene Evaluation (MORE) trial.
Presented at the 15th Annual Meeting of the North American Menopause Society, the CORE trial involved a subset of approximately 4,000 women who participated in MORE. MORE assessed raloxifene's efficacy in reducing breast cancer incidence over a 4-year period. CORE, in contrast, looked at the drug's impact on rates of endometrial cancer and hyperplasia and vaginal bleeding during the same period and for 4 years beyond.
Over the 8-year period, the placebo and raloxifene groups did not differ in incidence of uterine cancer, endometrial hyperplasia, ovarian cancer, or vaginal bleeding. There were also similar rates of self-reported pelvic organ prolapse in the two groups. Overall, there were 11 uterine cancers, 11 cases of endometrial hyperplasia, five ovarian cancers, and 41 cases of vaginal bleeding reported.
Intentional weight loss linked to lower mortality in postmenopausal women
March 11th 2025A recent study shows that intentional weight loss significantly lowers all-cause, cancer, and cardiovascular mortality risks among postmenopausal women, highlighting the importance of targeted weight management.
Read More